Literature DB >> 22507819

A Mexican way to cope with stem cell grafting.

Guillermo J Ruiz-Delgado1, Guillermo J Ruiz-Argüelles.   

Abstract

The widespread practice of stem cell grafting faces several problems in the world, derived mainly from the high costs of the procedure when conducted using traditional methods. In order to cope with this problem, we have implemented in México procedures to make stem cell grafting, both autologous and allogeneic, more affordable to patients living in our country and in other developing countries. The simplification of these procedures which have been done in our country are described; they have resulted in and increased number of patients both autografted and allografted in México. In the case of autografts, the changes have relied on the use of non-frozen autologous peripheral blood stem cells and short conditioning schedules delivered as outpatients, whereas in the case of allografts, changes have relied mainly in conducting the allografts fully on an outpatient basis and employing reduced-intensity conditioning preparative schedules.

Entities:  

Mesh:

Year:  2012        PMID: 22507819     DOI: 10.1179/102453312X13336169157130

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  8 in total

1.  Costs of hematopoietic stem cell transplantation in a developing country.

Authors:  Monica M Rivera-Franco; Eucario Leon-Rodriguez; Haydee L Castro-Saldaña
Journal:  Int J Hematol       Date:  2017-06-14       Impact factor: 2.490

2.  Publications of bone marrow transplants in Latin America. A report of the Latin American Group of Bone Marrow Transplantation.

Authors:  G J Ruiz-Argüelles; V Abello-Polo; C Arrais-Rodrígues; L F Bouzas; C de Souza; G Dufort; R Gabus; L S Galindo-Becerra; D Gómez-Almaguer; N Hammerschlak; J C Jaime-Fagundo; G Jaimovich; A J Karduss-Urueta; N Labastida-Mercado; M Nese; R Pasquini; A Seber
Journal:  Bone Marrow Transplant       Date:  2015-05-11       Impact factor: 5.483

3.  Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center.

Authors:  G J Ruiz-Argüelles; J C Olivares-Gazca; M Olivares-Gazca; A A Leon-Peña; I Murrieta-Alvarez; Y Cantero-Fortiz; G B Gomez-Cruz; A Ruiz-Argüelles; M Priesca-Marin; G J Ruiz-Delgado
Journal:  Clin Exp Immunol       Date:  2019-08-19       Impact factor: 4.330

Review 4.  Haematopoietic cell transplants in Latin America.

Authors:  R P Gale; A Seber; C Bonfim; M Pasquini
Journal:  Bone Marrow Transplant       Date:  2016-03-21       Impact factor: 5.483

5.  Cost of hematopoietic stem cell transplantation in India.

Authors:  Sanjeev Kumar Sharma; Dharma Choudhary; Nitin Gupta; Mayank Dhamija; Vipin Khandelwal; Gaurav Kharya; Anil Handoo; Rasika Setia; Arpita Arora
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-07-01       Impact factor: 2.576

6.  JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement.

Authors:  J A Snowden; E McGrath; R F Duarte; R Saccardi; K Orchard; N Worel; J Kuball; C Chabannon; M Mohty
Journal:  Bone Marrow Transplant       Date:  2017-03-27       Impact factor: 5.483

7.  Bone Marrow Transplantation in Patients With Acute Leukemia In Cuba: Results From the Last 30 Years and New Opportunities Through International Collaboration.

Authors:  José Carnot Uria; Calixto Hernández Cruz; Jorge Muñío Perurena; Wilfredo Torres Yribar; Jesús Diego de la Campa; Concepción Del Castillo Carrillo; Yusaima Rodríguez Fraga; Julio A López Silva; Kali Cepero Llauger; Ibis K Pardo Ramírez; Aliette García García; Karen Sweiss; Pritesh R Patel; Damiano Rondelli
Journal:  J Glob Oncol       Date:  2018-12

8.  Beyond Biology: Impact of Center- and Country-specific Economic Factors on Outcomes After Hematopoietic Cell Transplantation.

Authors:  Nandita Khera
Journal:  EBioMedicine       Date:  2015-12-12       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.